HomeNewsTrendsNHAI to delay InvIT launch till road traffic is restored to pre-COVID-19, second wave levels

NHAI to delay InvIT launch till road traffic is restored to pre-COVID-19, second wave levels

Fall in toll collection due to the outbreak of the second wave and lockdowns being imposed by different states across the country have caused the company to defer decision; other asset monetization plans also put on hold

June 08, 2021 / 20:00 IST
Story continues below Advertisement
Representative Image (Image: NHAI)
Representative Image (Image: NHAI)

The National Highways Authority of India (NHAI) plans to delay the launch of its maiden Infrastructure Investment Trust (InvIT) till such time that traffic on the highways is back in full volume, its officials told Moneycontrol.

The NHAI had earlier planned to launch its InvIT by the end of May or by the beginning of June after getting Securities and Exchange Board of India (SEBI) approvals, but a fall in toll collection due to the outbreak of the second wave of COVID and lockdowns being imposed by different states across the country have caused the company to defer this decision.

Story continues below Advertisement

"A sharp fall in toll collections in May coupled with predictions of a third wave of COVID-19 have led to uncertainty in the minds of investors looking at the (road) sector," a company official admitted.

According to rating agency Icra, toll collections fell by around 10 percent in April 2021 over March 2021 and are estimated to have declined by 25-30 percent in May 2021 over April 2021.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show